ArticleThe Journal of clinical psychiatry2015
Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys.
Article in The Journal of clinical psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018Pooled it
- Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder.Molecular psychiatry · 2018Trial
- Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study.Journal of child and adolescent psychopharmacology · 2018Trial
- Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth.Journal of child and adolescent psychopharmacology · 2016Trial
- Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing.The mental health clinician · 2021Article
- Antipsychotic therapies and bone health.Case reports in women's health · 2020Article
- Management of Self-injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview.Pharmacotherapy · 2019Review
- Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs.Clinical neuropsychiatry · 2019Article
- CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders.Journal of affective disorders · 2018Article
- Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys.The Journal of pediatrics · 2018Observational
- The Impact of Psychotropic Medications on Bone Health in Youth.Current psychiatry reports · 2018Review
- Nutrition and Bone Density in Boys with Autism Spectrum Disorder.Journal of the Academy of Nutrition and Dietetics · 2018Article
- CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents.Journal of child and adolescent psychopharmacology · 2017Observational
- Bone Mineral Density in Boys Diagnosed with Autism Spectrum Disorder: A Case-Control Study.Journal of autism and developmental disorders · 2017Article
- Article
- Bone Accrual in Males with Autism Spectrum Disorder.The Journal of pediatrics · 2017Article
- Elucidating the Mechanism(s) Underlying Antipsychotic and Antidepressant-Mediated Fractures.Journal of mental health & clinical psychology · 2017Article
- Bone Density in Adolescents and Young Adults with Autism Spectrum Disorders.Journal of autism and developmental disorders · 2016Article
- Calcium and Vitamin D Supplement Prescribing Practices among Providers Caring for Children with Autism Spectrum Disorders: Are We Addressing Bone Health?Autism research and treatment · 2016Article
- The effect of psychostimulants on skeletal health in boys co-treated with risperidone.The Journal of pediatrics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveIn a previous cross-sectional study, we found lower bone mass during treatment with selective serotonin reuptake inhibitors (SSRIs) and risperidone in youths. Here, we evaluate the skeletal effects of these psychotropics at follow-up.
methodBetween April 2005 and July 2011, medically healthy 7- to 17-year-old males treated with risperidone for 6 months or more were enrolled through child psychiatry outpatient clinics and returned for follow-up 1.5 years later. Treatment history was extracted from the medical and pharmacy records. Anthropometric, laboratory, and bone mass measurements were obtained. Multivariable linear regression analyses compared participants who remained on risperidone at follow-up to those who had discontinued risperidone treatment as well as SSRI-treated versus SSRI-unexposed participants.
resultsThe sample consisted of 94 boys with a mean age of 11.8 ± 2.7 years at study entry. The majority had an externalizing disorder and had received risperidone and SSRIs for 2.5 ± 1.7 years and 1.6 ± 1.9 years, respectively, at study entry. By follow-up, 26% (n = 24) had discontinued risperidone. Compared to discontinuing risperidone, continuing it was associated with a decline in participants' age-sex-height-race-specific areal bone mineral density (BMD) z score at the lumbar spine (P < .04) and failure to increase radius trabecular volumetric BMD (P < .03), after accounting for significant covariates. In addition, receiving an SSRI was associated with reduced lumbar spine areal BMD z score and radius trabecular volumetric BMD at both study entry (P < .02 and P < .03, respectively) and follow-up (P < .06 and P < .03, respectively), but without further decline between the 2 visits.
conclusionsChronic SSRI treatment in children and adolescents is associated with reduced, albeit stable, bone mass for age, while chronic risperidone treatment is associated with failure to accrue bone mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.